Condition
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Advanced or Metastatic Non-small Cell Lung Cancer clinical trials that are recruiting, at sites in 20 countries (most in China (5), Belgium (1), Brazil (1)). By phase: Phase 1/2 (3), Phase 3 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 20Countries
Newest Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| SHR-8068 with adebrelimab and chemotherapy versus tislelizumab with chemotherapy for first-line advanced or metastatic non-small cell lung cancer | Phase 3 | Jinan, Shandong | Recruiting | Sep 12, 2025 |
| Platform of new drug combinations for advanced non-small cell lung cancer | Phase 1/2 | Phoenix, Arizona and 102 other locations | Recruiting | May 30, 2025 |
| Furmonertinib for advanced lung cancer with specific EGFR mutations | Phase 3 | Beijing, Beijing Municipality | Recruiting | Nov 5, 2024 |
| Evaluating IAP0971 for advanced malignant tumors | Phase 1/2 | Beijing, Beijing Municipality | Recruiting | Sep 3, 2024 |
| Combining SHR-A2102 and Adebrelimab for Advanced Lung Cancer | Phase 1/2 | Beijing, Beijing Municipality | Recruiting | Jul 22, 2024 |
All recruiting trials (5)
-
SHR-8068 with adebrelimab and chemotherapy versus tislelizumab with chemotherapy for first-line advanced or metastatic non-small cell lung cancer
This trial will test whether SHR-8068 plus adebrelimab with platinum chemotherapy works better than tislelizumab with platinum chemotherapy as first treatment for adults with newly diagnosed advanced or metastatic non-small cell lung cancer.
-
Platform of new drug combinations for advanced non-small cell lung cancer
This will test rilvegostomig given with platinum-based chemotherapy, with or without ramucirumab, in people with advanced or metastatic non-small cell lung cancer whose tumors have PD-L1 TPS ≥1%.
-
Furmonertinib for advanced lung cancer with specific EGFR mutations
This study is testing a new treatment called furmonertinib to see if it helps people with advanced lung cancer who have certain genetic mutations feel better and live longer.
-
Evaluating IAP0971 for advanced malignant tumors
This study is testing a new treatment called IAP0971 to see if it is safe and effective for people with advanced lung cancer.
-
Combining SHR-A2102 and Adebrelimab for Advanced Lung Cancer
This study is testing a new combination of two drugs, SHR-A2102 and Adebrelimab, to see if they can help people with advanced lung cancer feel better and improve their treatment outcomes.
Related topics
Quick answers
How many Advanced or Metastatic Non-small Cell Lung Cancer clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 20 countries. The most sites are in China (5 trials), Belgium (1 trial), Brazil (1 trial), France (1 trial), Georgia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.